Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study
CANCER RESEARCH. Bd. 81. H. 4. 2021
Erscheinungsjahr: 2021
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Wockel, Achim (Autor)
Brucker, Cosima (Autor)
Decker, Thomas (Autor)
Falbrede, Jorg (Autor)
Forstbauer, Helmut (Autor)
Gohler, Thomas (Autor)
Hoffmann, Oliver (Autor)
Jackisch, Christian (Autor)
Janssen, Jan (Autor)
Kohler, Andreas (Autor)
Ludtke-Heckenkamp, Kerstin (Autor)
Luftner, Diana (Autor)
Marme, Frederik (Autor)
Nusch, Arnd (Autor)
Reimer, Toralf (Autor)
Roos, Christian (Autor)
Schmidt, Marcus (Autor)
Weide, Rudolf (Autor)
Fasching, Peter (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
